A protocol to develop clinical guidelines for inclusion‐body myositis

INTRODUCTION: Inclusion‐body myositis (IBM) is a late‐onset idiopathic inflammatory myopathy associated with selective and progressive muscle weakness and atrophy. Current clinical management of IBM is largely supportive due to its uncertain etiology and lack of effective treatment. Establishing a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Katherine L., Sejersen, Thomas, Amato, Anthony A., Hilton‐Jones, David, Schmidt, Jens, Wallace, Amanda C., Badrising, Umesh A., Rose, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Issues & Opinions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067551/
https://www.ncbi.nlm.nih.gov/pubmed/26800092
http://dx.doi.org/10.1002/mus.25036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067551/
https://www.ncbi.nlm.nih.gov/pubmed/26800092
http://dx.doi.org/10.1002/mus.25036

Ejemplares similares